Research programme: stem cell therapy-cardiac disease - ViaCell/Centocor

Drug Profile

Research programme: stem cell therapy-cardiac disease - ViaCell/Centocor

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Centocor; ViaCell
  • Developer Cordis Corporation
  • Class
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Heart failure; Myocardial infarction

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Heart-failure in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Myocardial-infarction in USA
  • 04 Oct 2015 Cordis Corporation has been acquired by Cardinal Health
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top